Fig. 3.

Association of i17q in medulloblastoma with DFS. Similar to other published studies, i17q was associated with more frequent recurrences and shorter disease-free intervals. Although a trend is observed showing a worse outcome for positive cases, it approaches but does not meet statistical significance (log-rank, Wilcoxon P = .085, .071, respectively). Mean DFS was shorter in the positive group at 50.3 months (CI, 19.9–80.6 months) compared with 111.4 months (CI, 84.4–138.4 months) in the i17q-negative group. Assessing the effect of i17q on OS was difficult given the number of (see Supplementary material, Fig. S2).